Scholarlink

Background <p>New antibody–drug conjugates (ADCs) and their presumably sequential use require intensified supportive and interdisciplinary management in patients with relapsed ovarian cancer (OC).</p> Objective <p>This paper summarizes current aspects of supportive care and interdisciplinary collaboration related to the application of new ACDs.</p> Materials and methods <p>This paper is based on a&#xa0;selective literature search in the PubMed database on the subject of “supportive care with ADCs in relapsed ovarian cancer” from 2020 onwards.</p> Results <p>Only mirvetuximab soravtansine (MIRV), as a&#xa0;new ADC, is currently approved by the European Medicines Agency (EMA) for treatment of platinum-refractory OC. Here, the challenge is ocular toxicity, which requires continuous ophthalmological surveillance and eyedrop medication strategies. Other ADCs under clinical investigation, such as luveltamab tazevibulin (LUVELTA), which, similar to MIRV, targets the folate receptor alpha, show no relevant ocular toxicity but lead to clinically relevant (febrile) neutropenia. Trastuzumab deruxtecan (T-DXd) has not (yet) been approved for relapsed OC but shows very good data for this entity; T‑DXd requires not only tight clinical control but also regular computed tomography of the chest to monitor for interstitial lung disease. T‑DXd should be considered highly emetogenic and requires premedication with anti-emetogenic triple therapy.</p> Conclusion <p>The new ADCs lead to relevant survival advantages in relapsed OC which are only achievable if the optimal therapeutic density is reached by the best possible supportive care and clear multidisciplinary networking plans.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Interdisziplinäres Therapiemanagement von Antikörper-Wirkstoff-Konjugaten beim rezidivierten Ovarialkarzinom

  • 期刊论文

  • 发表日期：

    2025年3月17日

查看全文
  • Diana Lüftner,
  • Kerstin Stahlhut,
  • Michael Untch,
  • Gottfried Konecny

摘要

Background

New antibody–drug conjugates (ADCs) and their presumably sequential use require intensified supportive and interdisciplinary management in patients with relapsed ovarian cancer (OC).

Objective

This paper summarizes current aspects of supportive care and interdisciplinary collaboration related to the application of new ACDs.

Materials and methods

This paper is based on a selective literature search in the PubMed database on the subject of “supportive care with ADCs in relapsed ovarian cancer” from 2020 onwards.

Results

Only mirvetuximab soravtansine (MIRV), as a new ADC, is currently approved by the European Medicines Agency (EMA) for treatment of platinum-refractory OC. Here, the challenge is ocular toxicity, which requires continuous ophthalmological surveillance and eyedrop medication strategies. Other ADCs under clinical investigation, such as luveltamab tazevibulin (LUVELTA), which, similar to MIRV, targets the folate receptor alpha, show no relevant ocular toxicity but lead to clinically relevant (febrile) neutropenia. Trastuzumab deruxtecan (T-DXd) has not (yet) been approved for relapsed OC but shows very good data for this entity; T‑DXd requires not only tight clinical control but also regular computed tomography of the chest to monitor for interstitial lung disease. T‑DXd should be considered highly emetogenic and requires premedication with anti-emetogenic triple therapy.

Conclusion

The new ADCs lead to relevant survival advantages in relapsed OC which are only achievable if the optimal therapeutic density is reached by the best possible supportive care and clear multidisciplinary networking plans.